Forns J, Esnaola M, Lopez-Vicente M, Suades-Gonzalez E, Alvarez-Pedrerol M, Julvez J, Grellier J, Sebastian-Galles N, Sunyer J. The n-back test and the attentional network task as measures of child neuropsychological development in epidemiological studies. Neuropsychology. 2014 Jul;28(4):519-29. doi: 10.1037/neu0000085
Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222
Lopez-Vicente M, Sunyer J, Forns J, Torrent M, Julvez J. Continuous Performance Test II outcomes in 11-year-old children with early ADHD symptoms: a longitudinal study. Neuropsychology. 2014 Mar;28(2):202-11. doi: 10.1037/neu0000048
Mauskopf J, Chirila C, Graham J, Gersten ID, Leather H, Maziarz RT, Baden LR, Bolanos-Meade J, Brown JMY, Walsh TJ, Horowitz MH, Kurtzberg J, Marr KA, Wingard JR. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. Am J Health Syst Pharm. 2013 Sep;70(17):1518-27.
Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.
Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, Papadopoulos G. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high risk patients. Am J Health Syst Pharm. 2009 Oct;66(19):1711-7. doi: 10.2146/ajhp080325.
Talbird SE, Brogan AJ, Winiarski AP, Sander B. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States. Am J Health Syst Pharm. 2009 Mar 1;66(5):469-80.